1. Home
  2. Proprotein convertase
  Subject:

Proprotein convertase   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
RELATED SUBJECTS:
The publications listed also have these subjects
Subtilisin  12 times
Low-density lipoprotein  6 times
Lipoprotein  6 times
Statin  5 times
Dyslipidemia  5 times
Cardiovascular disease  5 times
Cholesterol  4 times
Diabetes mellitus  3 times
Coronary artery disease  3 times
Atherosclerosis  3 times
Zygosity  2 times
Protease  2 times
Monoclonal antibody  2 times
MicroRNA  2 times
Metabolism  2 times
Hypercholesterolemia  2 times
Fenofibrate  2 times
Enzyme inhibitor  2 times
Enzyme  2 times
Blood lipids  2 times
Atorvastatin  2 times
Transcription factor  1 time
Syndrome  1 time
Sterol  1 time
Sodium  1 time
Serum albumin  1 time
Proteinuria  1 time
Protein kinase B  1 time
Protein  1 time
Prednisolone  1 time
Placebo  1 time
Omega-3 fatty acid  1 time
NF-κB  1 time
Mouse  1 time
Messenger RNA  1 time
Mechanistic target of rapamycin  1 time
Luciferase  1 time
Lipopolysaccharide  1 time
Lipid  1 time
Kinase  1 time
Japan  1 time
Intraperitoneal injection  1 time
Interleukin 10  1 time
Hypertension  1 time
Hyperlipidemia  1 time
Human genome  1 time
Hormone  1 time
Homeostasis  1 time
Histopathology  1 time
Hepatocellular carcinoma  1 time
Glycated hemoglobin  1 time
Glucose  1 time
Glucagon-like peptide-1  1 time
Genome-wide association study  1 time
Genome  1 time
Force-feeding  1 time
Diabetes mellitus type 2  1 time
DNA sequencing  1 time
Cytokine  1 time
Critical Role  1 time
Cofactor (biochemistry)  1 time
ClinicalTrials.gov  1 time
Chromium  1 time
Cell surface receptor  1 time
Cas9  1 time
Carcinoma  1 time
CRISPR  1 time
C-Jun N-terminal kinases  1 time
Blood sugar  1 time
Aorta  1 time
Antibody  1 time
Angiotensin II receptor blocker  1 time
Ancient Rome  1 time
Albumin  1 time
Albinism  1 time
Adrenocorticotropic hormone  1 time
Acid  1 time
ACE inhibitor  1 time

Publications tagged with this subject: 13

Note: Top 50 publications shown only. Open an item panel to view more info (open all)


1. Knockdown of microRNA-17-5p ameliorates atherosclerotic lesions in ApoE−/− mice and restores the expression of very low density lipoprotein receptor

2. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report

3. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells

4. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

5. Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia

6. Genetics of Dyslipidemia and Ischemic Heart Disease

7. Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers

8. PCSK9 signaling pathways and their potential importance in clinical practice

9. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

10. Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

11. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing

12. Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

13. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice


Questions?

Drop us a message.